Bart Filius joins Galapagos as CFO
(Thomson Reuters ONE) -
Mechelen, Belgium; 15 October 2014 - Galapagos NV (Euronext: GLPG) announced
today that Bart Filius, currently Vice President, CFO Sanofi Europe, will join
Galapagos as Chief Financial Officer, effective 1 December 2014. Bart will join
the Executive Committee of Galapagos and be responsible for Finance, Investor
Relations, IT, and Purchasing.
Bart Filius has over 13 years' experience at Sanofi. During the past three years
as CFO Sanofi Europe, Bart was instrumental in transforming the Sanofi European
organization to be well-positioned beyond the patent cliff. Earlier at Sanofi,
Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he
was Vice President for Mergers & Acquisitions, during which time Bart led and
completed the divestiture of various franchises.
Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little.
Bart is a Dutch national and has an MBA degree from INSEAD and a bachelor's
degree in business from Nyenrode University.
"We are pleased to welcome Bart Filius into our Executive team," said Onno van
de Stolpe, CEO of Galapagos. "His vast experience in Big Pharma and his sharp
strategic view will help us bring Galapagos to the next level, as we prepare to
have our rheumatoid arthritis molecule GLPG0634 enter Phase 3 and progress more
programs into patients next year."
"I am very excited to join Galapagos at this important point of its
development", said Bart Filius. "As we move forward and the pipeline matures
further, I look forward to bringing my experience in Finance and M&A to
Galapagos."
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-
clinical, and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics and metabolic disease. In the field of
inflammation, AbbVie and Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and other
inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in
Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184
(formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). AbbVie and
Galapagos signed an agreement in cystic fibrosis to develop and commercialize
molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is
expected to start Phase 1 in 2014. Galapagos also expects to nominate a pre-
clinical candidate corrector before year end 2014. The Galapagos Group,
including fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1862954]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Vida Green, Ltd. Invited to Join Water Treatment Alliance Datum: 15.10.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 344039
Anzahl Zeichen: 5355
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bart Filius joins Galapagos as CFO"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
